EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal

Norah A Terrault iD, Richard Sterling iD, Anna S Lok iD, Marc G Ghany iD, Jordan J Feld iD, Gavin Cloherty, Abdus S Wahed iD, Xue Yang iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae541 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Norah A Terrault und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Abbott Diagnostics, Hepatitis B Research Network, Intramural Research Program of the National Institute of Diabetes and Digestive Diseases and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Withdrawal of nucleos(t)ide analogue therapy is associated with hepatitis B surface antigen (HBsAg) loss and sustained off-therapy partial cure (normal alanine aminotransferase [ALT] ≤30 U/L for males and ≤20 U/L for females with hepatitis B virus [HBV] DNA <2000 IU/mL) but should be offered only to those most likely to benefit. HBV RNA may be useful for risk stratification.

Methods

The Hepatitis B Research Network Immune-Active Trial prospectively evaluated treatment with tenofovir disoproxil fumarate (TDF) for 192 weeks ± peginterferon alfa-2a for the initial 24 weeks, followed by protocolized withdrawal of TDF among eligible participants (ClinicalTrials.gov NCT01369212). HBV RNA was evaluated as a predictor of ALT flares and sustained partial cure (HBV DNA <2000 IU/mL) 48 weeks after TDF withdrawal.

Results

Of 93 participants discontinuing TDF (n = 52, TDF + peginterferon alfa-2a; n = 41, TDF alone), 52 (55.9%) had unquantifiable HBV RNA at end of treatment. ALT flares >5 times the upper limit of normal at 48 weeks off therapy occurred in 33.3%, with pretreatment age (≥35 years) and quantifiable HBV RNA at end of treatment the best predictors (area under the receiver operating characteristic curves, 0.74 and 0.85 for training and test sets, respectively). A total of 26 (28.3%) had sustained partial cure, 3 (11.5%) with ALT flare. Nonquantifiable HBV RNA and quantitative HBsAg <100 IU/mL at end of treatment were the best predictors of sustained partial cure (area under the receiver operating characteristic curves, 0.84 and 0.93 for training and test sets). If HBV RNA was quantifiable at end of treatment, the likelihood of sustained partial cure was only 3%, whereas if HBV RNA was unquantifiable and quantitative HBsAg was <100 IU/mL, this likelihood was 73%.

Conclusions

HBV RNA is a useful biomarker in predicting likelihood of achieving sustained partial cure and safe withdrawal of nucleos(t)ide analogues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis BHepatitis B virusHepatitis B, ChronicRNA, ViralTenofovirAdultFemaleHumansMaleMiddle AgedAlanine TransaminaseBiomarkersDNA, ViralHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsProspective StudiesRecombinant ProteinsWithholding Treatment

Stichwörter der Autor:innen

ALT flareHBsAg lossfunctional curepartial curepeginterferon

Substanzen

Alanine TransaminaseAntiviral AgentsBiomarkersDNA, ViralHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRNA, Viral

Autor:innen und Institutionen

  • Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles.
  • Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond.
  • Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor.
  • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
  • Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada.
  • Infectious Disease Research, Abbott Diagnostics, Abbott Park, Illinois.

ORCID-Profile: Norah A Terrault, Richard Sterling, Anna S Lok, Marc G Ghany, Jordan J Feld, Abdus S Wahed, Xue Yang

Förderung

  • Abbott Diagnostics
  • Hepatitis B Research Network
  • Intramural Research Program of the National Institute of Diabetes and Digestive Diseases and Kidney Diseases
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Terrault, N. A., Sterling, R., Lok, A. S., Ghany, M. G., Feld, J. J., Cloherty, G., Wahed, A. S., & Yang, X. (2025). Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae541

Vancouver

Terrault NA, Sterling R, Lok AS, Ghany MG, Feld JJ, Cloherty G, et al. Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae541

BibTeX
@article{Terrault2025,
  author = {Terrault, Norah A and Sterling, Richard and Lok, Anna S and Ghany, Marc G and Feld, Jordan J and Cloherty, Gavin and Wahed, Abdus S and Yang, Xue},
  title = {Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae541}
}
Kostenlos starten →